GlassScriptPhysician profile
Mallory Davis
NPI 1942843438
$2,782.19
in general payments reported to CMS, 2019-2025
31 companies · $814 in 2025
The $814 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $568 · 2022: $496 · 2023: $572 · 2024: $332 · 2025: $814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,718.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $420.06 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $401.74 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $373.76 | 2021-2025 | |
| Lilly USA, LLC | $158.59 | 2021-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $132.09 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Inspire Medical Systems, INC. | $121.66 | 2023 | Inspire |
| Amgen INC. | $121.59 | 2021-2022 | |
| Myovant Sciences INC. | $115.82 | 2022 | |
| Corium, LLC | $115.57 | 2023-2024 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $103.98 | 2021-2025 | Trintellix |
| Cmp Pharma, INC. | $83.79 | 2022 | |
| Janssen Pharmaceuticals, INC | $81.87 | 2021-2022 | |
| Dexcom, INC. | $66.03 | 2024-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $58.95 | 2022-2025 | |
| Genentech USA, INC. | $53.00 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $43.16 | 2023 | |
| Axonics, INC. | $37.98 | 2021 | |
| Amarin Pharma, INC. | $32.25 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.31 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.04 | 2021-2022 | |
| Exact Sciences Corporation | $26.99 | 2023-2024 | Cologuard Collection Kit |
| Ardelyx, INC. | $24.56 | 2024 | Ibsrela |
| Kowa Pharmaceuticals America, INC. | $21.98 | 2025 | Zoryve |
| Boston Scientific Corporation | $20.76 | 2021 | |
| Adlon Therapeutics L.P. | $18.64 | 2021 | |
| Shield Therapeutics INC | $18.19 | 2022 | |
| Alnylam Pharmaceuticals INC. | $17.73 | 2021 | |
| Collegium Pharmaceutical, INC. | $16.28 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $12.63 | 2021 | |
| Medtronic, INC. | $12.33 | 2022 | |
| Astellas Pharma US INC | $11.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mallory Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.